Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL

Bodvael Pennarun; Jan H. Kleibeuker; Wytske Boersma-van Ek; Frank A. E. Kruyt; Harry Hollema; Elisabeth G. E. de Vries; Steven de Jong

doi:10.1002/path.4138

Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL

Bodvael Pennarun, Jan H. Kleibeuker, Wytske Boersma-van Ek, Frank A. E. Kruyt, Harry Hollema, Elisabeth G. E. de Vries, Steven de Jong^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

31 Citations (Scopus)

Abstract

The multikinase inhibitor sorafenib is highly effective against certain types of cancer in the clinic and prevents colon cancer cell proliferation in vitro. Non-steroidal anti-inflammatory drugs, such as acetylsalicylic acid (aspirin), have shown activity against colon cancer cells. The aims of this study were to determine whether the combination of aspirin with sorafenib has enhanced anti-proliferative effects and increases recombinant human tumour necrosis factor-related apoptosis-inducing ligand (rhTRAIL)-induced apoptosis in the human SW948, Lovo, Colo205, Colo320, Caco-2 and HCT116 colon cancer cell lines. In four cell lines, aspirin strongly stimulated the anti-proliferative effects of sorafenib (similar to four-fold enhancement) by inducing cell cycle arrest. Furthermore, combining low doses of aspirin (

Original language	English
Pages (from-to)	410-421
Number of pages	12
Journal	The Journal of Pathology
Volume	229
Issue number	3
DOIs	https://doi.org/10.1002/path.4138
Publication status	Published - Feb-2013

Keywords

aspirin
sorafenib
TRAIL
FLIP
Mcl-1
APOPTOSIS-INDUCING LIGAND
NONSTEROIDAL ANTIINFLAMMATORY DRUGS
BCL-2 HOMOLOG BAX
COLORECTAL-CANCER
C-FLIP
CARCINOMA CELLS
DOWN-REGULATION
LEUKEMIA-CELLS
CYTOCHROME-C
DEATH LIGAND

Access to Document

10.1002/path.4138

Handle.net

Persistent link

Cite this

@article{ad5a0f67dc7848379c6f7bd3066d3b49,

title = "Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL",

abstract = "The multikinase inhibitor sorafenib is highly effective against certain types of cancer in the clinic and prevents colon cancer cell proliferation in vitro. Non-steroidal anti-inflammatory drugs, such as acetylsalicylic acid (aspirin), have shown activity against colon cancer cells. The aims of this study were to determine whether the combination of aspirin with sorafenib has enhanced anti-proliferative effects and increases recombinant human tumour necrosis factor-related apoptosis-inducing ligand (rhTRAIL)-induced apoptosis in the human SW948, Lovo, Colo205, Colo320, Caco-2 and HCT116 colon cancer cell lines. In four cell lines, aspirin strongly stimulated the anti-proliferative effects of sorafenib (similar to four-fold enhancement) by inducing cell cycle arrest. Furthermore, combining low doses of aspirin (",

keywords = "aspirin, sorafenib, TRAIL, FLIP, Mcl-1, APOPTOSIS-INDUCING LIGAND, NONSTEROIDAL ANTIINFLAMMATORY DRUGS, BCL-2 HOMOLOG BAX, COLORECTAL-CANCER, C-FLIP, CARCINOMA CELLS, DOWN-REGULATION, LEUKEMIA-CELLS, CYTOCHROME-C, DEATH LIGAND",

author = "Bodvael Pennarun and Kleibeuker, {Jan H.} and {Boersma-van Ek}, Wytske and Kruyt, {Frank A. E.} and Harry Hollema and {de Vries}, {Elisabeth G. E.} and {de Jong}, Steven",

year = "2013",

month = feb,

doi = "10.1002/path.4138",

language = "English",

volume = "229",

pages = "410--421",

journal = "The Journal of Pathology",

issn = "0022-3417",

publisher = "Wiley",

number = "3",

}

TY - JOUR

T1 - Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL

AU - Pennarun, Bodvael

AU - Kleibeuker, Jan H.

AU - Boersma-van Ek, Wytske

AU - Kruyt, Frank A. E.

AU - Hollema, Harry

AU - de Vries, Elisabeth G. E.

AU - de Jong, Steven

PY - 2013/2

Y1 - 2013/2

N2 - The multikinase inhibitor sorafenib is highly effective against certain types of cancer in the clinic and prevents colon cancer cell proliferation in vitro. Non-steroidal anti-inflammatory drugs, such as acetylsalicylic acid (aspirin), have shown activity against colon cancer cells. The aims of this study were to determine whether the combination of aspirin with sorafenib has enhanced anti-proliferative effects and increases recombinant human tumour necrosis factor-related apoptosis-inducing ligand (rhTRAIL)-induced apoptosis in the human SW948, Lovo, Colo205, Colo320, Caco-2 and HCT116 colon cancer cell lines. In four cell lines, aspirin strongly stimulated the anti-proliferative effects of sorafenib (similar to four-fold enhancement) by inducing cell cycle arrest. Furthermore, combining low doses of aspirin (

AB - The multikinase inhibitor sorafenib is highly effective against certain types of cancer in the clinic and prevents colon cancer cell proliferation in vitro. Non-steroidal anti-inflammatory drugs, such as acetylsalicylic acid (aspirin), have shown activity against colon cancer cells. The aims of this study were to determine whether the combination of aspirin with sorafenib has enhanced anti-proliferative effects and increases recombinant human tumour necrosis factor-related apoptosis-inducing ligand (rhTRAIL)-induced apoptosis in the human SW948, Lovo, Colo205, Colo320, Caco-2 and HCT116 colon cancer cell lines. In four cell lines, aspirin strongly stimulated the anti-proliferative effects of sorafenib (similar to four-fold enhancement) by inducing cell cycle arrest. Furthermore, combining low doses of aspirin (

KW - aspirin

KW - sorafenib

KW - TRAIL

KW - FLIP

KW - Mcl-1

KW - APOPTOSIS-INDUCING LIGAND

KW - NONSTEROIDAL ANTIINFLAMMATORY DRUGS

KW - BCL-2 HOMOLOG BAX

KW - COLORECTAL-CANCER

KW - C-FLIP

KW - CARCINOMA CELLS

KW - DOWN-REGULATION

KW - LEUKEMIA-CELLS

KW - CYTOCHROME-C

KW - DEATH LIGAND

U2 - 10.1002/path.4138

DO - 10.1002/path.4138

M3 - Article

SN - 0022-3417

VL - 229

SP - 410

EP - 421

JO - The Journal of Pathology

JF - The Journal of Pathology

IS - 3

ER -

Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this